FDA staff questions Lilly drug for Alzheimer’s test
Tuesday, January 18th, 2011U.S. health reviewers’ main concern with Eli Lilly & Co’s imaging agent for Alzheimer’s tests is whether technicians can properly read the scans and how useful they are in assessing the degenerative disease.
Read more:
FDA staff questions Lilly drug ... continue reading